Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme Replacement Therapy for Pancreatic Insufficiency
People with exocrine pancreatic insufficiency currently face highly disruptive pill burden – ANG003 expected to only require one tablet per meal NEW YORK & NATICK, Mass.–(BUSINESS WIRE)–Blackstone Life Sciences (“BXLS”) today announced a $250 million…